FDA Approves Eli Lilly's Tirzepatide for Cardiovascular Risk Reduction in Type 2 Diabetes

On August 28, Eli Lilly said the U.S. Food and Drug Administration (FDA) approved a new indication for tirzepatide, a GIP/GLP-1 receptor agonist, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who have elevated cardiovascular risk, according to Jiemian News. The approved use covers the risk of cardiovascular death, nonfatal heart attack, or nonfatal stroke.